The protective activity of Thymex L against radiotherapeutically-induced cellular immunodepression in lung cancer patients.
In order to prevent the radiotherapeutically-induced aggravation of initial immunodeficiency, a thymic preparation (Thymex L) was given to lung cancer patients simultaneously with irradiation. The parameters of both cellular and humoral nonspecific immunity were evaluated in two groups of patients: one was treated with radiotherapy only (60 Gy in 30 fractions); the other one received Thymex L (100 mg 3 times a week, total dose 1800 mg, i.m.) simultaneously with radiotherapy. The significant decrease of B and T cell number, and decreased lymphoproliferative response to PHA were found in all patients before therapy; the number and phagocyting capacity of blood monocytes, as well as the concentrations of circulating IgG, IgA and immunocomplexes, were all significantly increased. Immediately after irradiation the patients had even lower number of T and B cells, diminished reactivity to PHA and higher number of mononuclear phagocytes when compared to the values before therapy. In patients treated with Thymex L, the number of B and T cells and PHA-induced proliferative response were significantly higher than in those treated with radiotherapy only. No effect of this therapy was seen on active T cells, on high number and function of mononuclear phagocytes and on elevated concentrations of serum immunoglobulins and immune complexes. Our results indicate that Thymex L can successfully prevent the harmful effect of radiation therapy on cellular immunity in a majority of lung cancer patients.
Vucković-Dekić
L J
LJ
Institute of Oncology and Radiology, Beograd, Yugoslavia.
Susnjar
S
S
Stanojević-Bakić
N
N
Rajner
L
L
Frim
O
O
D000328:Adult; D000368:Aged; D001402:B-Lymphocytes / Q000528:radiation effects; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood / Q000276:immunology* / Q000532:radiotherapy; D005260:Female; D006801:Humans; D007070:Immunoglobulin A / Q000528:radiation effects; D007074:Immunoglobulin G / Q000528:radiation effects; D007153:Immunologic Deficiency Syndromes / Q000209:etiology; D007963:Leukocytes, Mononuclear / Q000528:radiation effects; D008175:Lung Neoplasms / Q000097:blood / Q000276:immunology* / Q000532:radiotherapy; D008297:Male; D008875:Middle Aged; D010586:Phagocytes / Q000528:radiation effects; D011837:Radiation-Protective Agents / Q000627:therapeutic use*; D011878:Radiotherapy / Q000009:adverse effects; D013601:T-Lymphocytes / Q000528:radiation effects; D013949:Thymus Extracts / Q000627:therapeutic use*
D007070:Immunoglobulin A; D007074:Immunoglobulin G; D011837:Radiation-Protective Agents; D013949:Thymus Extracts